Status:
COMPLETED
PPAR-COMBO With Sulfonylurea
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Metabolics Diabetes Nos
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mell...
Eligibility Criteria
Inclusion
- Type 2 Diabetes, HbA1c \> 7.0% and \< 10.0%, mean serum triglyceride \< 600 mg/dL, body mass index \< 41 kg/m2, fasting c-peptide . 1.5 ng/mL.
Exclusion
- History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months, congestive heart failure (NYHA Class III and IV, uncontrolled hypertension, history or renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
534 Patients enrolled
Trial Details
Trial ID
NCT00162175
Start Date
July 1 2003
End Date
November 1 2005
Last Update
September 14 2010
Active Locations (149)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Anniston, Alabama, United States
2
Local Institution
Hoover, Alabama, United States
3
Local Institution
Huntsville, Alabama, United States
4
Local Institution
Mobile, Alabama, United States